Business
Cabaletta Bio Announces 2026 Strategic Priorities
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment cleared to manufacture rese-cel with the automated, scalable Cellares platform based on multiple successful engineering runs; clinical manufacturing data expected in 1H26 to confirm GMP readiness, including supply chain logistics New durability data without preconditioning and higher dose initial cl
About this update from Cabaletta Bio, Inc.
[{"type":"image","alt":"Cabaletta Bio","displaySize":"","headline":null,"caption":"Cabaletta Bio","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":40,"url":"https://media.zenfs.com/en/globenewswire.com/f565214a2c1c703d1ed00c6d6b50d1de"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hszKHjsTAmj809exeTCP.w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f565214a2c1c703d1ed00c6d6b50d1de","width":300,"height":40}},"lazy":false},{"type":"text","content":"Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose ","length":185,"tagName":"p"},{"type":"text","content":"IND amendment cleared to manufacture rese-cel with the automated, scalable Cellares platform based on multiple successful engineering runs; clinical manufacturing data expected in 1H26 to confirm GMP readiness, including supply chain logistics ","length":243,"tagName":"p"},{"type":"text","content":"New durability data without preconditioning and higher dose initial clinical data from RESET-PV™ expected in 1H26; dose-ranging data from RESET-SLE™ without preconditioning anticipated in 2026","length":192,"tagName":"p"},{"type":"text","content":"Complete Phase 1/2 data anticipated in lupus, scleroderma and myasthenia gravis in 1H26","length":87,"tagName":"p"},{"type":"text","content":"FDA alignment on registrational study achieved in SLE and LN for small single-arm cohorts; strategically prioritizing no preconditioning regimen pending dose-ranging data ","length":170,"tagName":"p"},{"type":"text","content":"PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its 2026 strategic priorities to support development and launch of rese-cel (resecabtagene autoleucel) while advancing innovations to efficiently increase scale through automated manufacturing and expanding access for patients with autoimmune diseases.","length":536,"tagName":"p"},{"type":"text","content":"“In 2026, we are focused on enrolling our pivotal myositis trial to support the planned rese-cel B...